Filtered By:
Specialty: Pharmaceuticals
Condition: Chronic Obstructive Pulmonary
This page shows you your search results in order of date.
Order by Relevance | Date
Total 8 results found since Jan 2013.
Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Johnson Health Equity Innovation Challenge Awardees
NEW BRUNSWICK, N.J., June 14, 2022 – After an extensive search for the top changemakers in six key U.S. cities, Johnson & Johnson today announced the 14 awardees of its Health Equity Innovation Challenge. The awardees, who possess lived experience and a deep understanding of the communities they serve, were selected for their work in generating solutions to help close racial health and mortality gaps in six cities where Black and Brown individuals experience significant health inequities: Chicago, Detroit, Los Angeles, New Orleans, New York City and Philadelphia.The Health Equity Innovation Challenge was created by J...
Source: Johnson and Johnson - June 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Asthma, COPD Tied to Worse COVID-19 Outcomes
THURSDAY, Sept. 2, 2021 -- Patients with active asthma or chronic obstructive pulmonary disease (COPD) are at increased risk for severe COVID-19 outcomes, according to a study published online Aug. 10 in the Journal of Allergy and Clinical...
Source: Drugs.com - Pharma News - September 2, 2021 Category: Pharmaceuticals Source Type: news
Asthma, COPD Medication Adherence Up During Pandemic
FRIDAY, May 8, 2020 -- Medication adherence for asthma and chronic obstructive pulmonary disease (COPD) has increased during the COVID-19 pandemic, according to a study published online May 3 in the Journal of Allergy and Clinical Immunology: In...
Source: Drugs.com - Pharma News - May 8, 2020 Category: Pharmaceuticals Source Type: news
UAB Medicine partners with Guideway Care to manage COPD patients
Guideway Care will be entering into a guidance partnership with UAB Medicine for patients with chronic obstructive pulmonary disease, or COPD.
Financial terms of the deal were not disclosed.
“We know from previous experience at UAB in the realm of cancer care that lay navigators can improve access, coordinate care delivery and reduce costs for the health system,” said Anand Iyer, assistant professor in the UAB Division of Pulmonar y, Allergy, and Critical Care Medicine. “COPD is one of…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 24, 2018 Category: Pharmaceuticals Authors: Tyler Patchen Source Type: news
FDA Advisory Committee recommends approval in US of umeclidinium/vilanterol for the treatment of COPD
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol (UMEC/VI, 62.5/25mcg dose) for the long-term, once-daily, maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Source: GSK news - September 10, 2013 Category: Pharmaceuticals Source Type: news
FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for the treatment of COPD
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support approval of BREO™ ELLIPTA™ as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) (9 for, 4 against) and also for the reduction of COPD exacerbations in patients with a history of exacerbations (9 for, 4 against)*.
Source: GSK news - April 17, 2013 Category: Pharmaceuticals Source Type: news
FDA Advisory Committee Recommends Approval For Boehringer Ingelheim's Olodaterol For Maintenance Treatment Of COPD
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended that clinical data included in a new drug application (NDA) provide substantial and convincing evidence to support the approval of olodaterol as a once-daily maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Source: Pharmaceutical Online News - January 30, 2013 Category: Pharmaceuticals Source Type: news
